Business Context and Reporting Period
This Form 8-K Current Report was filed by Rhythm Pharmaceuticals, Inc. on July 25, 2019, covering events occurring on July 23, 2019. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Boston, MA. Its common stock trades on the Nasdaq Global Market under the symbol "RYTM".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors increased the size of the Board from seven to eight members. Stuart Arbuckle was appointed as a new director, designated as a Class I director to serve until the 2021 annual meeting of stockholders. Mr. Arbuckle was also appointed to the Compensation Committee and is considered an independent director.
Management Commentary and Background
Mr. Arbuckle brings significant commercial leadership experience, currently serving as Executive Vice President and Chief Commercial Officer at Vertex Pharmaceuticals. His prior roles include leadership positions at Amgen and 15 years at GlaxoSmithKline. He will be compensated in accordance with the Company's non-employee director compensation policy and will enter into a standard indemnification agreement. No other transactions or arrangements requiring disclosure under Item 404(a) of Regulation S-K exist.
Investor Verification Checklist
- Verify the appointment of Stuart Arbuckle to the Board and Compensation Committee.
- Review the Summary of Non-Employee Director Compensation Policy (Exhibit 10.1).
- Confirm the press release dated July 24, 2019 (Exhibit 99.1) for public announcement details.
- Note that this filing contains no financial performance data or guidance updates.